Vertex Pharmaceuticals (VRTX) Net Equity Issued and Repurchased (2009)
Vertex Pharmaceuticals' (VRTX) quarterly Net Equity Issued and Repurchased came in at $488.1 million in Q4 2009, up 976300.0% quarter-over-quarter from -$50000.0 in Q2 2009.
Vertex Pharmaceuticals (VRTX) Net Equity Issued and Repurchased (2009) Analysis & Trends
Vertex Pharmaceuticals' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $488.1 million for Q4 2009.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $488.1 million in Q4 2009; TTM through Dec 2009 was $801.3 million, a N/A change from a year earlier, with the FY2009 full-year figure at $801.4 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased grew to $488.1 million in Q4 2009 per VRTX's latest filing, from -$50000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $488.1 million in Q4 2009 and bottomed at -$50000.0 in Q2 2009.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 141.90 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | 488.10 Mn |
| Dec 31, 2009 | 488.10 Mn |
| Jun 30, 2009 | -50,000.00 |
| Jun 30, 2009 | -50,000.00 |
| Mar 31, 2009 | 313.30 Mn |
| Mar 31, 2009 | 313.30 Mn |